Sean Smith's Insider Trades & SAST Disclosures
Sean Smith's most recent trade in QXO Inc. was a trade of 1,040,298 Restricted Stock Unit done . Disclosure was reported to the exchange on July 30, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Sean Smith.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| QXO Inc. | Sean Smith | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jul 2024 | 1,040,298 | 1,040,298 | - | - | Restricted Stock Unit | |
| QXO Inc. | Sean Smith | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 9.14 per share. | 25 Jul 2024 | 27,353 | 27,353 (0%) | 0% | 9.1 | 250,006 | Common Stock, par value $0.00001 per share |
| Neoleukin Therapeutics Inc | Sean Smith | Interim CFO, Prin Acct Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2023 | 5,000 | 22,960 (0%) | 0% | 0 | Common Stock | |
| Neoleukin Therapeutics Inc | Sean Smith | Interim CFO, Prin Acct Off | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2023 | 5,000 | 0 | - | - | Restricted Stock Units | |
| Neoleukin Therapeutics Inc | Sean Smith | Interim CFO, Prin Acct Off | Sale of securities on an exchange or to another person at price $ 0.62 per share. | 10 Aug 2023 | 1,323 | 21,637 (0%) | 0% | 0.6 | 818 | Common Stock |
| Neoleukin Therapeutics Inc | Sean Smith | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 12,500 | 19,276 (0%) | 0% | 0 | Common Stock | |
| Neoleukin Therapeutics Inc | Sean Smith | Principal Accounting Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2023 | 12,500 | 12,500 | - | - | Restricted Stock Units | |
| Neoleukin Therapeutics Inc | Sean Smith | Principal Accounting Officer | Sale of securities on an exchange or to another person at price $ 0.60 per share. | 01 Feb 2023 | 3,316 | 15,960 (0%) | 0% | 0.6 | 1,980 | Common Stock |
| Permian Resources Corp - O... | Sean R. Smith | Director, Executive Chairman | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.62 per share. | 01 Sep 2022 | 424,558 | 3,038,779 (1%) | 0% | 7.6 | 3,235,132 | Class A Common Stock |
| Permian Resources Corp - O... | Sean R. Smith | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2022 | 178,784 | 3,463,337 (1%) | 0% | 0 | Class A Common Stock | |
| Permian Resources Corp - O... | Sean R. Smith | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Aug 2022 | 102,236 | 3,329,435 (1%) | 0% | 0 | Class A Common Stock | |
| Permian Resources Corp - O... | Sean R. Smith | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.29 per share. | 12 Aug 2022 | 44,882 | 3,284,553 (1%) | 0% | 7.3 | 327,190 | Class A Common Stock |
| Neoleukin Therapeutics Inc | Sean Smith | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Aug 2022 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Permian Resources Corp - O... | Sean R. Smith | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.54 per share. | 01 Aug 2022 | 51,371 | 3,227,199 (1%) | 0% | 6.5 | 335,966 | Class A Common Stock |
| Permian Resources Corp - O... | Sean R. Smith | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2022 | 220,000 | 3,278,570 (1%) | 0% | 0 | Class A Common Stock | |
| Neoleukin Therapeutics Inc | Sean Smith | Principal Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Permian Resources Corp - O... | Sean R. Smith | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.64 per share. | 01 Mar 2022 | 11,973 | 3,058,570 (1%) | 0% | 8.6 | 103,447 | Class A Common Stock |
| Permian Resources Corp - O... | Sean R. Smith | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.33 per share. | 11 Feb 2022 | 3,376 | 3,070,543 (1%) | 0% | 8.3 | 28,122 | Class A Common Stock |
| Permian Resources Corp - O... | Sean R. Smith | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.04 per share. | 01 Sep 2021 | 376,037 | 3,073,919 (1%) | 0% | 5.0 | 1,895,226 | Class A Common Stock |
| Permian Resources Corp - O... | Sean R. Smith | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.21 per share. | 30 Jul 2021 | 60,226 | 3,449,956 (1%) | 0% | 5.2 | 313,777 | Class A Common Stock |
| Permian Resources Corp - O... | Sean R. Smith | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jul 2021 | 331,577 | 3,510,182 (1%) | 0% | 0 | Class A Common Stock | |
| Permian Resources Corp - O... | Sean R. Smith | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.06 per share. | 01 Mar 2021 | 7,894 | 3,178,605 (1%) | 0% | 4.1 | 32,050 | Class A Common Stock |
| Permian Resources Corp - O... | Sean R. Smith | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.47 per share. | 12 Feb 2021 | 4,037 | 3,186,499 (1%) | 0% | 3.5 | 14,008 | Class A Common Stock |
| Permian Resources Corp - O... | Sean R. Smith | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.79 per share. | 31 Jul 2020 | 48,150 | 3,190,536 (1%) | 0% | 0.8 | 37,894 | Class A Common Stock |
| Permian Resources Corp - O... | Sean R. Smith | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2020 | 2,569,722 | 3,238,686 (1%) | 0% | 0 | Class A Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges